Gå direkt till huvudinnehållet

Val av preventivmedel

Senast uppdaterad: Senast reviderad:
Sakkunnig:

  1. Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med 1996; 41(5 suppl): 414-8.
  2. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007; 147: 370-6. Annals of Internal Medicine  
  3. Antikonception - behandlingsrekommendation. Läkemedelsverket 2014 www.lakemedelsverket.se  
  4. Juvkam KH, Gudim HB. Medikamentell behandling av menstruasjonsrelaterte plager. Tidsskr Nor Legeforen 2011; 9: 956-8. doi:10.4045/tidsskr.10.0300 DOI  
  5. Råd och riktlinjer från FARG, dokumentet "Långcykelbehandling 2016". www.sfog.se  
  6. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005; 46(suppl 9): 117-24.
  7. Steenland MW, Zapata LB, Brahmi D et al. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception. 2013 May;87(5):611-24. PMID: 23177264 PubMed  
  8. Oedingen C, Scholz S, Razum O. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose.. Thromb Res 2018; 165: 68-78. pmid:29573722 PubMed  
  9. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database of Syst Rev 2014; 3: CD010813. doi:10.1002/14651858.CD010813.pub2 DOI  
  10. Roach RE, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database of Syst Rev 2015, Issue 8. Art. No.: CD011054. DOI: 10.1002/14651858.CD011054.pub2. DOI  
  11. Weill A. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: Cohort study. BMJ 2016. doi:10.1136/bmj.i2002 DOI  
  12. Haider S, Darney PD. Injectable contraception. Clin Obstet Gynecol 2007; 50: 898-906. PubMed  
  13. Kaunitz AM. Depo-Provera's black box: time to reconsider? Contraception 2005; 72: 165-7. PubMed  
  14. A new progestin implant (Implanon) for long-term contraception. Obstet Gynecol 2007; 109: 990-1. PubMed  
  15. Funk S, Miller MM, Mishell DR Jr, et al.; Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319-26. PubMed  
  16. Bernstein CN, Blanchard JF, Houston DS, Wajda A.. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.. Thromb Haemost. 2001; Mar;85(3):: 430-4. doi:PMID: 11307809 PubMed  
  17. McCarthy L. Levonorgestrel-releasing intrauterine system (Mirena) for contraception. Am Fam Physician 2006; 73: 1799-1806. American Family Physician  
  18. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Nonlatex versus latex male condoms for contraception. Cochrane Database of Syst Rev 2006; 1: CD003550. doi:10.1002/14651858.CD003550.pub2 DOI  
  19. Berglund Scherwitzl E, Lundberg O, Kopp Kallner H et al. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. Contraception. 2017 Dec;96(6):420-425. PMID: 28882680 PubMed  
  20. Läkemedelsverket. Läkemedelsverkets granskning av Natural Cycles avslutad. Hämtad 2018-10-18. lakemedelsverket.se  
  21. Behandling av akne – behandlingsrekommendation. Läkemedelsverket (2014). www.lakemedelsverket.se  
  22. Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician 2003; 68: 697-704. PubMed  
  23. Begränsningar i användningen av cyproteron på grund av risk för meningeom. Nyheter 2020-02-19 medibas.se  
  24. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135. doi:10.1136/bmj.h2135 DOI  
  25. Mendoza N, Simoncini T, Genazzani AD. Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. Gynecol Endocrinol. 2014;30(12):850-60. PMID: 25254621 PubMed  
  26. Lopez LM, Grey TW, Stuebe AM, et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation.. Cochrane Database of Syst Rev 2015; 3: CD003988. doi:10.1002/14651858.CD003988.pub2 DOI  
  27. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453-72. PubMed  
  28. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews 2012; 3: CD002122. DOI: 10.1002/14651858.CD002122.pub2 DOI  
  29. Reiter L, Nakken KO. Prevensjon for kvinner som bruker antiepileptika. Tidsskr Nor Legeforen 2016; 136: 32-4. doi:10.4045/tidsskr.14.1559 DOI  
  30. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5: 265-74. PubMed  
  31. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46-52. PubMed  
  32. Westhoff C. Higher body weight does not affect NuvaRing's efficacy. Obstet Gynecol 2005; 105(suppl 4): 56S.
  33. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96. PubMed  
  34. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008; 358: 1262-70. New England Journal of Medicine  
  35. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443-50. New England Journal of Medicine  
  36. Cardoso F, Polónia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997; 59: 237-43. PubMed  
  37. Department of Reproductive Health, World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. 2009, www.who.int  
  38. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38: 2438-45. Stroke  
  39. Pagano HP, Zapata LB, Berry-Bibee EN, et al.. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception 2016 Dec; 94(6): 641-649. pmid:27364100 PubMed  
  40. Skovlund CW, Mørch LS, Kessing LV, et al. Association of Hormonal Contraception With Suicide Attempts and Suicides. Am J Psychiatry 2017 Nov 17; Epub ahead of print: appiajp201717060616. pmid: 29145752Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016 Nov; 73(11): 1154-1162. pmid:27680324 PubMed  
  41. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016 Nov; 73(11): 1154-1162. pmid:27680324 PubMed  
  42. Lundin C, Danielsson KG, Bixo M et al.Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2016 Nov 29;76:135-143. PMID: 27923181 PubMed  
  43. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding.Cochrane Database of Syst Rev 2009; 4: CD000154. DOI: 10.1002/14651858.CD000154.pub2. DOI  
  44. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3):476-485. PMID: 27457513 PubMed  
  45. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies Circulation 1998; 98: 1058-63.
  46. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998; 29: 2277-84. Stroke  
  47. Mørch LS, Skovlund CW, Hannaford PC. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017 Dec 7;377(23):2228-2239. PMID: 29211679 PubMed  
  48. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. pmid:29346467 PubMed  
  • Kristina Gemzell-Danielsson, professor och överläkare, Kvinnokliniken, Karolinska universitetssjukhuset
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet